Extending the Time for Thrombolysis in Emergency Neurological Deficits
Status:
Completed
Trial end date:
2018-08-27
Target enrollment:
Participant gender:
Summary
The primary hypothesis being tested in this trial is that ischaemic stroke patients selected
with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of
stroke will have improved clinical outcomes when given intravenous tissue plasminogen
activator (tPA) compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Neuroscience Trials Australia
Collaborators:
Brain Research Institute Commonwealth Scientific and Industrial Research Organisation, Australia Melbourne Health The Florey Institute of Neuroscience and Mental Health University of Melbourne